







Sector leading performance across various ESG ratings providers

Agency	Rating	Score		Industry perspective ⁸
		Current	Previous	
 ¹	Score	▲ 4.18	3.2	2 / 20
 ²	Climate score	▼ B	A-	Management band B/B- ⁹
	Water score	▼ A-	A	Leadership band A/A- ⁹
 ^{2,3}	ESG score	▶ B	B	4 / 473
 ^{2,4}	ESG score	▶ A	A	
	MSCI Global Compact	▲ Pass	Watchlist	Best rated peers: AAA (3 PharmaCos), AA (10 PharmaCos)
	Controversy ⁷	▲ 3	1	
 ^{2,5}	ESG score	▲ 84	73	5 / 91 in Pharmaceuticals (97 th percentile)
 ^{2,6}	Risk score	▲ 17	21	
	Controversy level	▶ 3	3	1 / 432 in Pharmaceutical subindustry group ¹⁰

1. Published every 2nd year. Result shown shows 2020/2018 scores 2. 2021/ 2020 scores 3. Published every 2nd year. Updated December 2021 4. Updated December 2021 5. Updated March 2022. Novartis has been a DJSI World member since 2002 6. Updated April 2021 7. 0-10 scale, 0 being most severe controversy 8. Leadership as defined by rating agencies 9.Climate: Novartis received a B (Management band), same as the Biotech & pharma sector average, Water: Novartis received a A-(Leadership band), higher than the Biotech & pharma sector average 10. Pharmaceuticals subindustry group: traditional Pharma, excl. Biotech